In this context, a deeper capability to detect and categorize the diverse EGFR exon 20 insertion variants will be key to optimizing treatment selection and dosing in order to boost TKI efficacy and address the challenges posed by this distinct subset of NSCLC in currently ongoing and future studies. This evidence concerns the gene EGFR and non-small cell lung carcinoma.